Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.34 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25038067 | 0.91 | CYP2A6 (0.44) | PDK2CYP2A6SLC6A3HSD11B1SLC6A4 | |
| SCHEMBL25038158 | 0.91 | PDK2 (0.39) | PDK2CYP2A6SLC6A3HSD11B1SLC6A4 | |
| SCHEMBL23609480 | 0.88 | PDK2 (0.42) | PDK2HSD11B1AKR1A1AKR1B1 | |
| SCHEMBL24316403 | 0.88 | PDK2 (0.40) | PDK2CYP2A6SLC6A3HSD11B1AKR1A1 | |
| SCHEMBL22780112 | 0.87 | PDK2 (0.45) | PDK2HSD11B1AKR1A1AKR1B1CA1 | |
| SCHEMBL29733681 | 0.87 | PDK2 (0.45) | PDK2HSD11B1AKR1A1AKR1B1CA1 | |
| SCHEMBL25501424 | 0.85 | PDK2 (0.38) | PDK2HSD11B1AKR1A1AKR1B1 | |
| SCHEMBL25879053 | 0.83 | CYP2A6 (0.37) | PDK2CYP2A6SLC6A4LMNAMAPT | |
| SCHEMBL30593260 | 0.82 | PDK2 (0.41) | PDK2HSD11B1 | |
| SCHEMBL23959624 | 0.82 | PDK2 (0.41) | PDK2HSD11B1AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230052660-A1 | NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| WO-2022068292-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | 陕西莱特光电材料股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | OR51E2, SQLE, ODC1 | PDK2 327/4885CYP2A6 178/4885SLC6A3 558/4885 |
| US-20230052660-A1 | NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | NOD1, NFE2L2, NOTCH1 | PDK2 3491/4885CYP2A6 899/4885SLC6A3 4182/4885 |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | LEF1, OCIAD1, OR10J3 | PDK2 705/4885CYP2A6 504/4885SLC6A3 3896/4885 |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | NOD1, NFE2L2, NOTCH1 | PDK2 3491/4885CYP2A6 899/4885SLC6A3 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.